InhibitorPenghambat PCSK9 adalah kelas obat yang lebih baru, yang disetujui oleh FDA pada tahun 2015, yang menghambat enzim buatan hati (PCSK9), yang biasanya memecah reseptor LDL.[57][58]<ref>{{Cite journal |last1=Hess |first1=Paul L. |last2=Kennedy |first2=Kevin |last3=Cowherd |first3=Michael |last4=Virani |first4=Salim S. |last5=Masoudi |first5=Frederick A. |last6=Navar |first6=Ann Marie |last7=Yeh |first7=Robert W. |last8=Ho |first8=P. Michael |last9=Maddox |first9=Thomas M. |date=January 2018 |title=Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project |journal=American Heart Journal |volume=195 |pages=151–152 |doi=10.1016/j.ahj.2017.09.004 |issn=1097-6744 |pmc=5961484 |pmid=29224643}}</ref><ref>{{Cite web |last=MD |first=Alyson Kelley-Hedgepeth |date=2020-06-08 |title=Are statins enough? When to consider PCSK9 inhibitors |url=https://www.health.harvard.edu/blog/are-statins-enough-when-to-consider-pcsk9-inhibitors-2020060819986 |access-date=2024-11-14 |website=Harvard Health |language=en}}</ref> Reseptor LDL berfungsi untuk membuang kolesterol dari aliran darah. Jadi, dengan menghambat enzim (PCSK9) yang memecah reseptor LDL, lebih banyak reseptor LDL yang tersedia untuk menurunkan lipid dalam aliran darah.[59]<ref>{{Citation |last1=Pokhrel |first1=Binod |title=PCSK9 Inhibitors |date=2024 |work=StatPearls |url=https://www.ncbi.nlm.nih.gov/books/NBK448100/ |access-date=2024-11-14 |place=Treasure Island (FL) |publisher=StatPearls Publishing |pmid=28846236 |last2=Pellegrini |first2=Mark V. |last3=Levine |first3=Steven N.}}</ref> InhibitorPenghambat PCSK9 biasanya diresepkan sebagai terapi tambahan untuk statin lini pertama. Efek sampingnya dapat mencakup gejala seperti [[flu]] dan nyeri/bengkak di tempat suntikan.[60]<ref>{{Cite journal |last1=Gürgöze |first1=Muhammed T. |last2=Muller-Hansma |first2=Annemarie H.G. |last3=Schreuder |first3=Michelle M. |last4=Galema-Boers |first4=Annette M.H. |last5=Boersma |first5=Eric |last6=Roeters van Lennep |first6=Jeanine E. |date=February 2019 |title=Adverse Events Associated With PCSK 9 Inhibitors: A Real-World Experience |journal=Clinical Pharmacology & Therapeutics |language=en |volume=105 |issue=2 |pages=496–504 |doi=10.1002/cpt.1193 |issn=0009-9236 |pmc=6704355 |pmid=30053327}}</ref>
